Cecilia Carpio

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Journal: Blood advances

Published: December 04, 2025

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Journal: Blood advances

Published: December 04, 2025

Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy.

Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy.

Journal: Pharmaceutics

Published: October 27, 2025

Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.

Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.

Journal: Leukemia & lymphoma

Published: August 20, 2025

CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis.

CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis.

Journal: Bone marrow transplantation

Published: August 11, 2025

Use of Dasatinib for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome After Axicabtagene Ciloleucel Infusion: A Case Report.

Use of Dasatinib for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome After Axicabtagene Ciloleucel Infusion: A Case Report.

Journal: European journal of haematology

Published: July 01, 2025

Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy.

Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy.

Journal: Bone marrow transplantation

Published: May 30, 2025

The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma.

The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 06, 2025

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.

Journal: Nature cancer

Published: April 16, 2025

A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial.

A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial.

Journal: British journal of haematology

Published: February 23, 2025

Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy.

Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy.

Journal: European journal of neurology

Published: February 18, 2025

Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy.

Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy.

Journal: Leukemia

Published: January 11, 2025

Showing 1-12 of 53

Last Updated: 09/26/2026